Sareum Holdings plc (SAR) ORD GBP0.0125
![](https://online.hl.co.uk/img/hl/layout/security-nochange-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-nochange-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-nochange-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Sareum announces positive results from kinase inhibitor trial
1 July 2024 11:23
(Sharecast News) - Sareum Holdings announced positive topline results from its phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor under development for treating autoimmune diseases.
-
Sareum allowed European patent for primary kinase inhibitor asset
15 March 2024 13:11
(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor...
-
Sareum reports positive progress in psoriasis programme
15 February 2024 13:22
(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.
-
Sareum shares jump on cancer drug licensing deal
2 January 2024 13:54
(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US...
-
Sareum secures Japan patent for kinase inhibitor asset
3 November 2023 13:59
(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase...
-
Sareum losses widen as clinical trials continue
9 October 2023 15:06
(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating...
-
Director dealings: Blackbird, Sareum insiders pick up shares
6 September 2023 14:35
(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.
-
Sareum granted new patents in China, US
26 June 2023 10:54
(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.
-
Sareum gets approval for phase one psoriasis studies in Australia
5 May 2023 15:53
(Sharecast News) - Biotechnology developer Sareum Holdings announced on Friday that it has been granted approval by Australia's Therapeutic Goods Administration (TGA) to conduct phase one clinical...
-
Sareum looks at options as GSK division returns cancer drug candidate
6 March 2023 16:16
(Sharecast News) - Biotechnology developer Sareum announced on Monday that GSK subsidiary Sierra Oncology has returned clinical study reports and associated documents related to 'SRA737' to...
-
Sareum confident despite recent setbacks
16 December 2022 16:55
(Sharecast News) - Autoimmune and cancer-focussed biotechnology company Sareum said in an update on Friday that it remained "confident" despite some recent setbacks.
-
Sareum progresses Covid-19 and autoimmune treatment candidate
16 March 2022 14:21
(Sharecast News) - Specialist drug developer Sareum Holdings updated the market on the development of its 'SDC-1801' - a potential Covid-19 and autoimmune disease treatment - towards first-in-human...
Company announcements Announcements
-
Management Changes
10 July 2024 07:00
Sareum Holdings
-
Positive Data from SDC-1801 Phase 1 Clinical Trial
1 July 2024 07:00
Sareum Holdings
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.